[OH:1][C@@H:2]([C@H:21]([OH:24])[CH2:22][OH:23])[CH2:3][O:4][C:5]1[C:14]2[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=2)[N:8]=[C:7]([N:15]2[CH2:20][CH2:19][NH:18][CH2:17][CH2:16]2)[N:6]=1.[ClH:25].CO>CO>[ClH:25].[OH:1][C@@H:2]([C@H:21]([OH:24])[CH2:22][OH:23])[CH2:3][O:4][C:5]1[C:14]2[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=2)[N:8]=[C:7]([N:15]2[CH2:20][CH2:19][NH:18][CH2:17][CH2:16]2)[N:6]=14-[(2R,3R)-(2,3,4-Trihydroxybutan-1-yl)oxy]-2-(1-piperazinyl)quinazoline (cf Example 64) (0.5 g) is dissolved in methanol (40 ml), and thereto is added 2N HCl-methanol (0.82 ml), and the mixture is evaporated to dryness under reduced pressure. The resulting residue is recrystallized from ethanol to give 4-[(2R,3R)-(2,3,4-trihydroxybutan-1-yl)oxy]-2-(1-piperazinyl)quinazoline monohydrochloride (0.14 g).
Loading…